Tango Therapeutics (TNGX) EBIT Growth (1y) (2021 - 2026)

Tango Therapeutics (TNGX) EBIT Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.32%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 19.82%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 145.20%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 269.85%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.24%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -36.55%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 1,528.74%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 99.51%
10 Tango Therapeutics 4.32 Bn 3.30 Bn - -45.93%

Historic Data

Download Data
DateValue
Jun 30, 2026 -45.93%
Mar 31, 2026 -14.67%
Dec 31, 2025 -2.33%
Sep 30, 2025 142.80%
Jun 30, 2025 -38.63%
Mar 31, 2025 -0.65%
Dec 31, 2024 -16.84%
Sep 30, 2024 -28.30%
Jun 30, 2024 -27.12%
Mar 31, 2024 -39.52%
Dec 31, 2023 -14.55%
Sep 30, 2023 14.36%
Jun 30, 2023 7.76%
Mar 31, 2023 -19.33%
Dec 31, 2022 -39.04%
Sep 30, 2022 -52.91%
Jun 30, 2022 -453.16%
Mar 31, 2022 -110.07%
Dec 31, 2021 -12,017.20%
Sep 30, 2021 26.86%